Comparison of Self- and Balloon-expandable Valves in Patients With Ascending Aortic Dilation Undergoing Transcatheter Aortic Valve Replacement: The AAD-CHOICE

Aortic Stenosis Clinical Trial

Official title:

Comparison of Self- and Balloon-expandable Valves in Patients With Ascending Aortic Dilation Undergoing Transcatheter Aortic Valve Replacement: The AAD-CHOICE

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT06009588
• Other study ID #: 2023-2024
• Status: Active, not recruiting
• Phase: N/A
• Start date: July 12, 2023
• Est. completion date: July 11, 2026

Study information

• Verified date: May 2024
• Source: China National Center for Cardiovascular Diseases
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aimed at comparing the performance of self-expandable valves versus balloon-expandable valves in patients with ascending aortic dilation undergoing transcatheter aortic valve replacement.

Description:

Ascending aortic (AA) dilation is a common feature in patients with aortic stenosis (AS), especially in those with bicuspid aortic valve (BAV). For patients undergoing surgical aortic valve replacement (SAVR), current guidelines recommend concomitant aortic repair or replacement if the diameter of AA exceeds 45mm to avoid aortic dissection or rupture.

Transcatheter aortic valve replacement (TAVR) has profoundly changed the clinical management of AS patients who cannot tolerate SAVR. For patients who are candidates for TAVR, simultaneous repair of a dilated AA can be technically difficult. The safety and feasibility of the procedure and the fate of AA after the procedure in these patients remain unclear. Moreover, there are limited data comparing the performance of self-expandable valves versus balloon-expandable valves in these patients. The aim of the present study is to evaluate the impact of type of transcatheter heart valves on intra-procedural device success and post-procedural AA progression in patients with dilated AA (≥45mm) undergoing TAVR.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 100
• Est. completion date: July 11, 2026
• Est. primary completion date: July 11, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years and older

Eligibility

Inclusion Criteria:

• Severe aortic stenosis;

• Transfemoral access;

• Preoperative aortic CT suggesting maximum ascending aortic diameter =45mm and <55mm;

• Anticipated life expectancy >1 year;

• Age = 65 years.

Exclusion Criteria:

• Dominant aortic regurgitation,;

• A history of SAVR or TAVR;

• A history of aortic surgery;

• Emergent TAVR.

Related Conditions & MeSH terms

• Aortic Stenosis
• Aortic Valve Stenosis

Intervention

Device:
• self-expandable valves
patients undergoing TAVR use self-expandable valves
• balloon-expandable valves
patients undergoing TAVR use balloon-expandable valves

Locations

Country	Name	City	State
China	National Center for Cardiovascular Disease, China & Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
China National Center for Cardiovascular Diseases

Country where clinical trial is conducted

China, 

References & Publications (1)

VARC-3 WRITING COMMITTEE:; Genereux P, Piazza N, Alu MC, Nazif T, Hahn RT, Pibarot P, Bax JJ, Leipsic JA, Blanke P, Blackstone EH, Finn MT, Kapadia S, Linke A, Mack MJ, Makkar R, Mehran R, Popma JJ, Reardon M, Rodes-Cabau J, Van Mieghem NM, Webb JG, Cohen DJ, Leon MB. Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research. J Am Coll Cardiol. 2021 Jun 1;77(21):2717-2746. doi: 10.1016/j.jacc.2021.02.038. Epub 2021 Apr 19. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	30-day all-cause mortality	all-cause mortality within 30 days after TAVR procedure	30 days after TAVR procedure
Primary	30-day adverse aortic events	aortic death, aortic dissection, or aortic rupture	30 days after TAVR procedure
Primary	The rate of device success	Device success is defined as following: Technical success (Freedom from mortality; Successful access, delivery of the device, and retrieval of the delivery system; Correct positioning of a single prosthetic heart valve into the proper anatomical location; Freedom from surgery or intervention related to the device or to a major vascular or access-related, or cardiac structural complication); Freedom from mortality; Freedom from surgery or intervention related to the device or to a major vascular or access-related or cardiac structural complication; Intended performance of the valve (mean gradient <20 mmHg, peak velocity <3 m/s, Doppler velocity index $0.25, and less than moderate aortic regurgitation)	30 days
Secondary	1-year all-cause mortality	all-cause mortality	1 year after TAVR procedure
Secondary	1-year cardiovascular mortality	Related to heart failure, cardiogenic shock, bioprosthetic valve dysfunction, myocardial infarction, stroke, thromboembolism, bleeding, tamponade, vascular complication, arrhythmia or conduction system disturbances, cardiovascular infection (e.g. mediastinitis, endocarditis), or other clear cardiovascular cause	1 year after TAVR procedure
Secondary	1-year adverse aortic events	aortic death, aortic dissection, or aortic rupture	1 year after TAVR procedure
Secondary	Ascending aortic diameter expansion rate =3mm/year	Expansion rate was calculated as the change of ascending aortic diameters (before the procedure and at the latest follow-up) divided by the follow-up period.	1 year after TAVR procedure
Secondary	Hospitalization (or re-hospitalization)	Any admission after the index hospitalization or study enrolment to an inpatient unit or hospital ward for =24 h, including an emergency department stay.; Hospitalizations planned for pre-existing conditions are excluded unless there is worsening of the baseline condition. Visits to urgent care centres or emergency departments <24 h may also be included if substantive intensification of therapy changes (e.g. heart failure episodes) are enacted (e.g. intravenous diuretics, significant increases in drug therapy dosages or addition of new pharmacotherapy agents)	1 year after TAVR procedure